ra-BEP-ra-zole 
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP), cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), photosensitivity, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).
F and E: hypocalcemia (especially if treatment duration ≥3 mo), hypokalemia (especially if treatment duration ≥3 mo), hypomagnesemia (especially if treatment duration ≥3 mo).
GI: abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, diarrhea, fundic gland polyps, nausea.
GU: acute tubulointerstitial nephritis.
MS: bone fracture, neck pain.
Neuro: dizziness, headache, malaise.
Misc: chills, fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR TUBULOINTERSTITIAL NEPHRITIS), systemic lupus erythematosus, vitamin B12 deficiency.
Drug-Drug:
(Generic available)
Gastroesophageal Reflux Disease
Duodenal Ulcers
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (Triple Therapy)
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Aciphex, Aciphex Sprinkle
Absorption: Delayed-release tablet is designed to allow rabeprazole, which is not stable in gastric acid, to pass through the stomach intact. Subsequently 52% is absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 96.3%.
Metabolism/Excretion: Mostly metabolized by the CYP3A4 and CYP2C19 isoenzymes in the liver; (the CYP2C19 enzyme system exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly ↑ rabeprazole concentrations and an ↑ risk of adverse effects); 10% excreted in feces; remainder excreted in urine as inactive metabolites.
Half-life: 1–2 hr.
(acid suppression)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 1 hr | unknown | 24 hr† |
†Suppression continues to increase over the first wk of therapy.
NDC Code*